Safety and pharmacokinetics of Alpha-1 MP (Prolastin®-C) in Japanese patients with alpha1-antitrypsin (AAT) deficiency

• Published in: Respiratory investigation Vol. 57; no. 1; pp. 89 - 96
• Main Authors: Seyama, Kuniaki, Nukiwa, Toshihiro, Sato, Tadashi, Suzuki, Masaru, Konno, Satoshi, Takahashi, Kazuhisa, Nishimura, Masaharu, Steinmann, Kimberly, Sorrells, Susan, Chen, Junliang, Hayashi, Ken-ichi
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.01.2019
• Subjects: AAT deficiency; Alpha1-proteinase inhibitor; Japanese; Pharmacokinetics; Safety; ALP; Alpha-1 MP; tmax; AAT deficiency; ALT; AUC; SD; Alpha1-proteinase inhibitor; Safety; HBV; Cmax; AST; AE; MedDRA; IV; Japanese; ICH; FVC; TEAE; AAT; t; HIV; GCP; SAE; FEV1; HCV; PK; HAV; Pharmacokinetics
• ISSN: 2212-5345; 2212-5353
• DOI: 10.1016/j.resinv.2018.09.006

Alpha1-Proteinase Inhibitor, Modified Process (Alpha-1 MP) is used for augmentation therapy in alpha1-antitrypsin deficiency (AATD), an extremely rare disease in Japan. Weekly doses of 60 mg/kg Alpha-1 MP have been shown to be safe and well tolerated in non-Japanese subjects, but the safety and pharmacokinetics (PK) have not been evaluated in Japanese subjects. The objectives of this study were to evaluate the safety and PK of 60 mg/kg Alpha-1 MP administered by weekly IV infusions over 8 weeks in Japanese subjects with AATD. This was a multicenter, open-label trial in Japanese adults aged ≥20 years with AATD. Samples for evaluation of serum alpha1-PI concentration and PK parameters were collected at 10 time points until the seventh day after the last dose at Week 8: immediately before dosing, immediately after dosing (time 0), and 0.25, 2, 4, 8, 24, 48, 120, and 168 hours after dosing. Four subjects were analyzed. The median tmax was 0.534 h. Mean ± SD values for t½, Cmax, and AUC0–7days were 150.4 ± 36.18 h, 174.2 ± 30.51 mg/dL, and 14,913.2 ± 1633.45 mg*h/dL, respectively. Mean trough concentration at week 8 was 55.4 ± 7.23 mg/dL. Alpha-1 MP therapy was safe, with no serious adverse events or deaths reported. Two treatment-emergent adverse events of fatigue in one subject were considered to be possibly related. The PK and safety of Alpha-1 MP in Japanese subjects with AATD were consistent with the Alpha-1 MP profile in non-Japanese subjects (ClinicalTrials.gov: NCT02870309; JAPIC CTI: JapicCTI-163160).